Jennifer Wheler

Founder and President @Navigate Bioconsulting

Consulting services for the biopharmaceutical industry and investment community to support the clinical development of transformational cancer therapies. Navigate brings in-depth knowledge of precision oncology to achieve high impact results.From focused strategic work to interim CMO leadership, Navigate engages with clients from the preclinical stage through IND, Phase 1/2 trials and clinical proof-of-concept. Navigate BioConsulting has a track record of achieving successful outcomes for clients based on-an extensive network of leading KOLs and PIs -effective, concise communication with internal and external stakeholders (C-suite, internal teams, BODs, investors, academic audiences)-up-to-date knowledge of competitive landscape across indications, translational research (preclinical, exploratory biomarkers), regulatory guidance (expedited approval pathways, project optimus, expansion cohorts, research biopsies) and clinical trial design-collaborative working style and effective leadership of internal teams-pragmatic, impactful problem-solving and precise execution Founded by Dr. Jennifer Wheler, a Yale and Memorial Sloan Kettering-trained oncologist, with 20+ years of clinical drug development experience including-MD Anderson Cancer Center: Principal Investigator on 30+ Phase 1 trials including early trials of Cabometyx®, Adcetris®, Rozlytrek® and Foundation One® CDx; designed inaugural tumor agnostic basket trial; designed and led first trial to evaluate matching of patients\' tumor genomic alterations to treatments (with Foundation Medicine)-Novartis (NIBR): Clinical Trial Leader for 3 novel IO agents; earliest clinical POC for any Novartis IO drug; designed novel biomarker-driven strategies and combination strategies-experienced Chief Medical Officer for public and private biotechs-Expertise in antibody-drug conjugates, bispecific antibodies, radiopharmaceuticals, small molecules and novel IO agents (10+ INDs)